We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website. You can decide for yourself which categories you want to deny or allow. Please note that based on your settings not all functionalities of the site are available.
Further information can be found in our privacy policy.
Recent Comments
Promising work, especially in light of FDA-approved AAV gene therapy entering the U.S. market early this year to restore vision in patients diagnosed with biallelic RPE65-mutation-associated retinal dystrophy.